title: Benefits of contingent screening vs primary screening by cell-free DNA testing: think again.
authors.affiliation: Leiden University Medical Centre, Department of Obstetrics, Leiden, The Netherlands.
authors.forename: D
authors.initials: D
authors.lastname: Oepkes
authors.affiliation: University Hospital La Paz, Madrid, Spain.
authors.forename: J L
authors.initials: JL
authors.lastname: Bartha
authors.affiliation: Medical University of Vienna, Vienna, Austria.
authors.forename: M
authors.initials: M
authors.lastname: Schmid
authors.affiliation: Genetic Institute, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
authors.forename: Y
authors.initials: Y
authors.lastname: Yaron
mesh_terms: D002474:Cell-Free System; D025063:Chromosome Disorders / Q000175:diagnosis*; D004247:DNA / Q000097:blood*; D005260:Female; D006801:Humans; D048208:Nuchal Translucency Measurement / Q000379:methods*; D011247:Pregnancy; D011261:Pregnancy Trimester, First; D011266:Pregnancy-Associated Plasma Protein-A / Q000378:metabolism; D011296:Prenatal Diagnosis / Q000379:methods*
chemical_list: D004247:DNA; D011266:Pregnancy-Associated Plasma Protein-A; C579283:PAPPA protein, human